Osteoarthritis (OA) is the most common form of arthritis, a degenerative joint disease characterized by the progressive breakdown of articular cartilage, leading to joint pain, stiffness, swelling, and reduced mobility. It primarily affects middle-aged and older adults, commonly involving the hands, knees, hips, neck, and lower back. The condition results from cartilage wear that allows bones to rub against each other, causing chronic discomfort and eventual bone-on-bone contact, bone spurs, and joint deformity. While the exact cause remains unclear, risk factors include aging, obesity, joint injury, genetic predisposition, and repetitive joint stress. Symptoms vary but typically include joint pain, stiffness, limited flexibility, crepitus (creaking or cracking sounds), and swelling. Although there is no cure, management strategies such as medications, physical therapy, weight control, exercise, and surgery in severe cases can help alleviate symptoms and improve quality of life. Osteoarthritis significantly impacts daily functioning and may lead to disability in advanced stages.
| Cat. No. |
Product Name |
CAS No. |
Purity |
Chemical Structure |
-
- HY-N0762
-
|
Isobavachin
|
31524-62-6 |
99.88% |
|
Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, UGT1A1, UGT1A9, and UGT2B7. Isobavachin suppresses MAPK activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease.
|
-
-
- HY-P10739
-
|
WYRGRL
|
1021155-39-4 |
99.88% |
|
WYRGRL is a selective, high-affinity collagen type II-binding peptide with a IC50 of 140 nM. Collagen type II is the most abundant and specific structural protein in the extracellular matrix of articular cartilage. WYRGRL can precisely target small-molecule compounds such as Dexamethasone (HY-14648) and nanocarrier-engineered exosomes to cartilage, significantly enhancing their therapeutic effects on osteoarthritis.
|
-
-
- HY-B2162B
-
|
Chondroitin sulfate sodium (from bovine)
|
9082-07-9 |
99.40% |
|
Chondroitin sulfate (Chondroitin polysulfate) sodium (from bovine)) is a sulfated linear polysaccharide extracted from bovine sources, belonging to glycosaminoglycans. Chondroitin sulfate sodium (from bovine) inhibits osteoclast-mediated bone resorption and exhibits antioxidant activity, which is negatively correlated with molecular weight. Chondroitin sulfate sodium (from bovine) can be used in studies related to osteoarthritis.
|
-
-
- HY-158231
-
|
Polyether F127 Diacrylate
|
|
|
|
Polyether F127 Diacrylate (F127DA) is an acrylated polyethylene glycol-polypropylene glycol-polyethylene glycol triblock copolymer. Polyether F127 Diacrylate rapidly crosslinks and cures into a gel under ultraviolet or visible light with the action of a photoinitiator. Polyether F127 Diacrylate exhibits excellent thermogelation properties and favorable biosafety. Polyether F127 Diacrylate can upregulate the Integrin-FAK pathway, enhance collagen production, increase the protein and gene expression levels of COL-1/SCX, and promote fibroblastic differentiation of periodontal ligament stem cells. Polyether F127 Diacrylate promotes periodontal ligament regeneration and reduces abnormal healing in a rat model of delayed replanted teeth. Polyether F127 Diacrylate promotes functional osteochondral regeneration in a rat model of osteoarthritis. Polyether F127 Diacrylate supports adipose tissue survival, rendering it suitable for breast reconstruction applications. Polyether F127 Diacrylate can be used in studies related to periodontal ligament injury, breast defect and osteoarthritis.
|
-
-
- HY-B0890
-
|
Zomepirac sodium salt
|
64092-48-4 |
99.63% |
|
Zomepirac sodium salt (McN-2783-21-98) is an orally active prostaglandin synthetase inhibitor. Zomepirac sodium salt blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac sodium salt can be used for the research of postoperative pain and osteoarthritis.
|
-
-
- HY-115373
-
|
RO314724
|
112105-54-1 |
|
|
RO314724 is a selective MMP-1 inhibitor. RO314724 chelates to the catalytic zinc ion within the active site of MMP-1 and forms a stable complex with MMP-1. RO314724 can be used for the research of osteoarthritis.
|
-
-
- HY-181698
-
|
MMP13-IN-6
|
|
|
|
MMP13-IN-6 (Compound 10a) is a MMP-13 inhibitor with a Ki value of 40 nM against hMMP-13. MMP13-IN-6 can be used in the research of osteoarthritis and rheumatoid arthritis.
|
-
-
- HY-W740983
-
|
Dexamethasone dipropionate
|
55541-30-5 |
|
|
Dexamethasone dipropionate is a Dexamethasone (HY-14648) ester. Dexamethasone dipropionate can be used in the research of osteoarthritis.
|
-
-
- HY-B0633D
-
|
Hyaluronic acid sodium (MW 200-1560)
|
9067-32-7 |
99.41% |
|
Hyaluronic acid sodium (MW 200-1560) is a biopolymer composed of repeating disaccharide units, with a molecular weight of 200-1560. Hyaluronic acid sodium is a major component of the extracellular matrix (ECM). It is synthesized on the plasma membrane. Hyaluronic acid sodium exerts its effects by binding to receptors CD44 and RHAMM. Hyaluronic acid sodium activates PI3K-Akt signaling. Hyaluronic acid sodium also enhances cell invasion and angiogenesis by promoting or stimulating the binding of proteolytic MMP-9 to the cell surface. Elevated hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion, and angiogenesis in digestive system cancers. Hyaluronic acid sodium is involved in tissue remodeling and rapid cell proliferation in several physiological processes, including embryonic morphogenesis and wound healing. Hyaluronic acid sodium can be used as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid sodium can be used as a drug delivery carrier for sodium butyrate, enhancing its anti-proliferative activity against breast cancer cell lines. Hyaluronic acid sodium can lubricate the corneal endothelium. Hyaluronic acid sodium can improve tissue hydration and enhance the resistance of cells to mechanical damage. Hyaluronic acid sodium has been conjugated with antibodies to ensure that the active compound continues to exert its effects at the site of inflammation. Hyaluronic acid sodium can be used in research in the fields of osteoarthritis, ophthalmology, cosmetic dermatology, oncology, and liver diseases.
|
-
-
- HY-W783268A
-
|
Matriptase-IN-2
|
1268874-09-4 |
99.87% |
|
Matriptase-IN-2 is a secondary amide inhibitor of matriptase derived from sulfonylated 3-amidinophenylalanine, with a Ki value of 5 nM. Matriptase acts as a novel initiator of cartilage matrix degradation in osteoarthritis, and Matriptase-IN-2 inhibits matriptase-mediated cartilage degradation. Matriptase-IN-2 is applicable for the research of osteoarthritis.
|
-
-
- HY-B2162D
-
|
Chondroitin sulfate (from chicken)
|
9007-28-7 |
99.61% |
|
Chondroitin sulfate (from chicken) (Chondroitin polysulfate (from chicken)) is an orally active, sulfated linear polysaccharide extracted from chickens, which belongs to glycosaminoglycans. Chondroitin sulfate (from chicken) reduces the phosphorylation levels of ERK1/2 and p38MAPK, inhibits the expression of inflammatory cytokines and MMP, and downregulates the levels of IL-1β, IL-6, TNF-α and PGE2. Chondroitin sulfate (from chicken) improves motor function, protects cartilage tissue, reverses chondrocyte aggregation, and regulates the structure of intestinal flora. Chondroitin sulfate (from chicken) can be used in research related to osteoarthritis.
|
-
-
- HY-B2162C
-
|
Chondroitin sulfate (from pig)
|
9007-28-7 |
|
|
Chondroitin sulfate (from pig) (Chondroitin polysulfate (from pig)) is a sulfated linear polysaccharide extracted from pigs, which belongs to glycosaminoglycans. Chondroitin sulfate (from pig) exerts inconsistent inhibitory effects on the resorptive activity of human osteoclasts. Chondroitin sulfate (from pig) can be used in studies related to osteoarthritis.
|
-
-
- HY-172696
-
|
DSPE-PEG2000-WYRGRL
|
|
|
|
DSPE-PEG2000-WYRGRL is a PEG compound which composed of DSPE and a cartilage-targeting peptide (WYRGRL). WYRGRL is a collagen II-targeting peptide that can bind to collagen II α1. DSPE-PEG2000-WYRGRL can be used for drug delivery.
|
-
-
- HY-P2612
-
|
WP9QY
|
199999-60-5 |
99.78% |
|
WP9QY is an inhibitor targeting TNFα and RANKL, which blocks the TNFα-TNFR1 interaction and inhibits TNFα-mediated apoptosis, cytotoxicity and bone destruction. WP9QY inhibits osteoclastogenesis and promotes osteoblast differentiation, induces chondrocyte proliferation and glycosaminoglycan production, and synergizes with TGF-β3 to promote chondrogenesis. WP9QY effectively repairs full-thickness articular cartilage defects in rabbits via intra-articular injection, and inhibits methylmercury-induced reduction of NeuN-positive cells in mouse brain slices. WP9QY can be applied to the research of diseases related to methylmercury-induced neuronal death, cartilage injury, osteoarthritis and bone loss.
|
-
-
- HY-P99677
-
|
Izenivetmab
|
2447755-72-6 |
|
|
Izenivetmab (ZTS-00075623) is an anti-NGFB IgG2κ monoclonal antibody. Izenivetmab shows anti-inflammatory and analgesic effects by targeting anti-nerve growth factor (NGF). Izenivetmab can be used for the research of osteoarthritis.
|
-
-
- HY-160822
-
|
AGG-523
|
920289-29-8 |
99.32% |
|
AGG-523 (PF-5212371) is an orally active, reversible, non-hydroxamate, zinc-binding selective inhibitor of ADAMTS4 and ADAMTS5 with IC50 of <0.03 and 0.04 μM. AGG-523 also inhibits MMP-2, -8, 12 activity AGG-523 attenuates release of aggrecanase-generated ARG-aggrecan fragments into synovial fluid, reduces surgery-induced ARG-aggrecan release in rat joint models, and inhibits aggrecanase activity to slow cartilage degradation. AGG-523 can be used for the research of osteoarthritis.
|
-
-
- HY-B0633E
-
|
Hyaluronic acid, low endotoxin
|
9004-61-9 |
|
|
Hyaluronic acid, low endotoxin (Hyaluronan, low endotoxin) is a biopolymer composed of repeating disaccharide units containing low levels of endotoxin. Hyaluronic acid is a major component of the extracellular matrix (ECM). It is synthesized on the plasma membrane. Hyaluronic acid exerts its effects by binding to receptors CD44 and RHAMM. Hyaluronic acid activates PI3K-Akt signaling. Hyaluronic acid also enhances cell invasion and angiogenesis by promoting or stimulating the binding of proteolytic MMP-9 to the cell surface. Elevated hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion, and angiogenesis in digestive system cancers. Hyaluronic acid is involved in tissue remodeling and rapid cell proliferation in several physiological processes, including embryonic morphogenesis and wound healing. Hyaluronic acid can be used as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid can be used as a drug delivery carrier for sodium butyrate, enhancing its anti-proliferative activity against breast cancer cell lines. Hyaluronic acid can lubricate the corneal endothelium. Hyaluronic acid can improve tissue hydration and enhance the resistance of cells to mechanical damage. Hyaluronic acid has been conjugated with antibodies to ensure that the active compound continues to exert its effects at the site of inflammation. Hyaluronic acid can be used in research in the fields of osteoarthritis, ophthalmology, cosmetic dermatology, oncology, and liver diseases.
|
-
-
- HY-164826
-
|
Acetyl zingerone
|
30881-23-3 |
99.34% |
|
Acetyl zingerone is an analog of Zingerone (HY-14621). Acetyl zingerone downregulates the expression of ROS metabolism-related genes, fibroblast senescence-related genes, keratinocyte differentiation-related genes, and IL-17A target genes. Acetyl zingerone inhibits the activities of MMP-1, MMP-3, and MMP-12, as well as the activation of NLRP3 inflammasome, pyroptosis (pyroptosis), ferroptosis (ferroptosis), cartilage destruction, and UVA-induced cyclobutane pyrimidine dimer formation. Acetyl zingerone upregulates the expression of collagen, proteoglycan, extracellular matrix glycoprotein, Notch pathway, and GPX4 gene, activates Nrf2 and HO-1, induces extracellular matrix synthesis and PINK1/Parkin-mediated mitophagy (mitophagy), and promotes chondrocyte survival. Acetyl zingerone alleviates the progression of osteoarthritis in mice. Acetyl zingerone can be used in research related to skin aging, inflammatory skin diseases, osteoarthritis, melanoma, and non-melanoma skin cancer.
|
-
-
- HY-142686A
-
|
SGK1-IN-3 hydrochloride
|
|
|
|
SGK1-IN-3 hydrochloride (Compound 3a) is an ATP-competitive SGK1 inhibitor with an IC50 of <1 nM against hSGK1. SGK1-IN-3 hydrochloride blocks the activity of CDK family members. SGK1-IN-3 hydrochloride serves as a P-glycoprotein substrate. SGK1-IN-3 can be used for the research of osteoarthritis.
|
-
-
- HY-100516
-
|
Cimicoxib
|
265114-23-6 |
98.02% |
|
Cimicoxib (UR-8880) is an orally active, blood-brain barrier-permeable COX-2 inhibitor that also exerts targeted inhibition on CYP2D15. It has an IC50 of 66 nM against hCOX-2, an IC50 of 1.6 μM against canine CYP2D15, and an IC50 of 0.056 μM against feline CYP2D15. By inhibiting the COX-2 pathway to reduce the production of thromboxane B2 and prostaglandin E2, Cimicoxib exerts antipyretic, anti-inflammatory and analgesic effects. Cimicoxib is metabolized by CYP2D15 to form demethyl-cimicoxib, undergoes glucuronidation via UDP-glucuronosyltransferases, and exhibits biphasic elimination kinetics in beagle dogs. Cimicoxib is widely used in studies of inflammatory diseases, osteoarthritis, and perioperative pain associated with orthopedic or soft tissue surgeries.
|
-
